25
Participants
Start Date
December 19, 2019
Primary Completion Date
June 14, 2024
Study Completion Date
June 14, 2024
Tazemetostat
400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.
Doxorubicin HCl
75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
Tazemetostat
800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
Placebo
Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond
Doxorubicin HCl
75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
National Taiwan University Hospital, Taipei
Columbia University Irving Medical Center, New York
University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Thomas Jefferson University Hospital, Philadelphia
Duke University Medical Center, Durham
Mayo Clinic-Jacksonville, Jacksonville
Sarah Cannon and HCA Research Institute, Nashville
The Ohio State University Comprehensive Cancer Center, Columbus
University of Michigan Medical Center, Ann Arbor
Washington University, St Louis
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
Sarah Cannon Research Institute at HealthONE, Denver
Sarcoma Oncology Research Center, Santa Monica
City of Hope Comprehensive Cancer Center, Duarte
Oregon Health and Science University, Portland
Fred Hutchinson Research Center, Seattle
Massachusetts General Hospital, Boston
Dana Farber Cancer Insititute, Boston
Dana Farber Cancer Institute, Boston
McGill University Faculty of Medicine - Royal Victoria Hospital, Montreal
Royal Marsden Foundation Trust, London
Lead Sponsor
Epizyme, Inc.
INDUSTRY